Rapid evolution of combination therapy in melanoma.
From the Earle A. Chiles Research Institute, Providence Cancer Center, Portland, OR.
Brendan D
BD
Curti
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001384:Azetidines / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage*; D007211:Indoles / Q000008:administration & dosage*; D048369:MAP Kinase Kinase 1 / Q000037:antagonists & inhibitors*; D008297:Male; D008545:Melanoma / Q000188:drug therapy*; D020929:Mitogen-Activated Protein Kinase Kinases / Q000037:antagonists & inhibitors*; D010091:Oximes / Q000008:administration & dosage*; D010880:Piperidines / Q000008:administration & dosage*; D048493:Proto-Oncogene Proteins B-raf / Q000037:antagonists & inhibitors* / Q000235:genetics*; D011728:Pyridones / Q000008:administration & dosage*; D011744:Pyrimidinones / Q000008:administration & dosage*; D013449:Sulfonamides / Q000008:administration & dosage*; D000077484:Vemurafenib
D001384:Azetidines; D007093:Imidazoles; D007211:Indoles; D010091:Oximes; D010880:Piperidines; D011728:Pyridones; D011744:Pyrimidinones; D013449:Sulfonamides; D000077484:Vemurafenib; C560077:trametinib; D048493:Proto-Oncogene Proteins B-raf; D048369:MAP Kinase Kinase 1; D020929:Mitogen-Activated Protein Kinase Kinases; C574276:cobimetinib; C561627:dabrafenib